UNSPSC 51273941: Epinephrine/prilocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273941 Epinephrine/prilocaine is a Commodity code under which state and local governments procure emergency-response pharmaceuticals and drug-management products, though recent solicitation activity shows limited direct alignment with the code's nominal scope. The three recent opportunities tagged to this code reflect broader pharmaceutical and medical supply procurement: Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually); the Texas Health and Human Services Commission posted a Request for Information to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit managers; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The issuing bodies span county health departments, state health agencies, and cooperative purchasing alliances supporting multiple state and local participants, indicating procurement distributed across county and state health infrastructure rather than concentrated in a single jurisdiction type.

Activity appears concentrated in Florida, Texas, and Minnesota with MMCAP participation spanning additional states including Oregon. The Seminole County IFB (IFB60459723LAS, response deadline July 26, 2023) represents direct county procurement for community health support with quarterly deliveries and fixed-fee pricing; the Texas HHS RFI (HHS0017013, posted April 3, 2026) signals early-stage state-level market research on prescription models without immediate contracting; and the MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-state pharmaceutical frameworks requiring cGMP and DSCSA compliance, comprehensive insurance coverage up to $5,000,000 per occurrence, and pricing submissions across flat, net, and WAC-minus structures with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation. The mismatch between the code's name and recent solicitations — naloxone, broad-spectrum generics and OTC products, and direct-to-manufacturer models — suggests this code sees minimal activity aligned to its epinephrine/prilocaine specification.